Dihexa for Autism Spectrum Disorder (ASD), MET Gene Variants & Neurodevelopmental Cognitive Support: rs1858830, HGF/c-Met, mGluR5 PET, Leucovorin & the 2026 UK Review

Around 700,000 children and adults in the UK are autistic — roughly 1% of the population, on National Autistic Society and NHS England Autism Statistics figures, with a 2023 BJGP population-based primary-care cohort study estimating that a further 150,000-500,000 adults aged 20-49 in England may be autistic but undiagnosed. 2025-2026 has been an extraordinary period in autism medicine and policy. March 2026: the NHS England Autism Statistics reported 270,701 patients with an open referral for suspected autism — 89.7% waiting longer than the 13 weeks recommended by NICE NG142. 10 March 2026: the FDA approved leucovorin (folinic acid) only for cerebral folate deficiency in confirmed FOLR1 mutation carriers, explicitly declining to approve it for autism after the January 2026 retraction of the Panda et al. European Journal of Pediatrics leucovorin-autism randomised trial. 12 December 2025: the FDA approved DAYBUE STIX (trofinetide powder, Acadia Pharmaceuticals) for Rett syndrome, with broad US launch in Q2 2026. January 2026: a brain-wide mGluR5 [18F]FPEB PET imaging study reported 16-23% lower mGluR5 availability across cortical regions in autistic adults. Against this backdrop, the MET receptor tyrosine kinase — the molecular target of Dihexa’s synaptogenic HGF/c-Met pharmacology — is one of the most replicated autism candidate genes in the literature: the Campbell et al. 2006 PNAS rs1858830 promoter C-allele family-based association, the Campbell 2007 Annals of Neurology postmortem ASD cortex MET-protein reduction, and the Eagleson & Levitt 2015 Mol Psychiatry MET-signalling forebrain circuit work. Does that mechanistic alignment mean Dihexa has anything to offer the UK’s 700,000 autistic people? This rigorous 2026 UK review covers what is actually known, what is speculation, and where the evidence is entirely absent. Readers may also want to read the closely related Dihexa for ADHD review (50-70% autism-ADHD comorbidity), the Dihexa for Anxiety & Chronic Stress review (40-50% anxiety comorbidity), the Dihexa for OCD review (substantial autism-OCD overlap), the Dihexa for Depression & Mood review (25-40% depression comorbidity), the Dihexa & BDNF mechanistic deep-dive (the molecular axis converging on autism circuit biology), the Dihexa Mechanism of Action page (HGF/c-Met biology) and the Fosgonimeton / Athira page (the closest HGF-pathway clinical evidence).

Autism in the UK in 2026: Scale, Definitions & the Diagnosis Crisis

Autism spectrum disorder (ASD) — recognised as a single diagnostic entity in DSM-5 (2013) and ICD-11 code 6A02 (2022) following the consolidation of the previously separate Asperger’s syndrome, PDD-NOS and autistic disorder categories — is defined by persistent differences in social communication and social interaction, alongside restricted, repetitive patterns of behaviour, interests or activities, with onset in the early developmental period and clinically significant functional impact. The National Autistic Society (NAS) position is that approximately 1% of UK children and adults are autistic — around 700,000 people. The most recent NHS England Autism Statistics document estimated prevalence of 1.5-1.9% in males and 0.2-0.5% in females (a sex ratio that is increasingly understood as artefactual, reflecting historical female under-diagnosis rather than true biological sex differences in autism risk).

The Brett et al. 2023 BJGP population-based cohort study estimated that 150,000-500,000 adults aged 20-49 in England may be autistic but undiagnosed — reflecting decades of under-recognition particularly in women, in adults without intellectual disability, in those whose presentations include the ‘internalised’ phenotype, and in adults from minoritised ethnic groups. The Lai & Baron-Cohen 2015 Molecular Autism female-phenotype work and the Hull et al. 2017 Journal of Autism and Developmental Disorders camouflaging paper laid the empirical foundations for the contemporary ‘late diagnosis in women’ story that has driven a marked increase in adult referrals.

For comparison, the US CDC ADDM Network reports a prevalence of approximately 1 in 36 (~2.8%) in 8-year-old children — substantially higher than UK figures, almost certainly reflecting differences in case ascertainment rather than true biology.

The March 2026 UK Diagnostic Crisis

The headline numbers from the NHS England Autism Statistics (April 2025 to March 2026) publication tell the story:

• 270,701 patients with an open referral for suspected autism in March 2026.
• 242,708 (89.7%) waiting longer than the 13 weeks recommended by NICE NG142.
• 12,750 new referrals and 13,153 closed referrals in March 2026 — a small narrowing but leaving a vast accumulated backlog.
• The November 2025 National Autistic Society analysis recorded the average waiting time increasing by approximately six months over the preceding 12-month period.
• The Nuffield Trust has formally documented this as one of the most pressing NHS access crises.
• The combined ADHD-and-Autism Payment Guidance for 2026-27 (NHS England, March 2026) acknowledged the scale of the workforce and capacity challenge without ring-fencing meaningful new funding.

The practical consequence is that thousands of UK adults are increasingly using the Right-to-Choose pathway under the NHS Constitution to seek diagnosis via independent providers including Psychiatry-UK, ProblemShared, Clinical Partners and others. The Retreat Clinics 2026 review catalogues current NHS, Right-to-Choose and private waiting times across the UK. A complete private diagnostic assessment typically costs £1,500-£3,500.

The MET Gene & Autism: The Strongest Molecular Anchor to Dihexa’s Pharmacology

The link between the MET receptor tyrosine kinase and autism is the single most direct, mechanistically grounded molecular alignment to Dihexa’s pharmacology of any condition this site has reviewed. The story has four pillars: the genetic association, the postmortem protein reduction, the cortical-circuit biology, and the convergence with environmental risk factors.

Pillar 1: rs1858830 — The Campbell Family-Based Association

The MET gene sits on chromosome 7q31, a region with longstanding linkage evidence for autism. Campbell et al. 2006 in Proceedings of the National Academy of Sciences USA reported a family-based association study in 204 Caucasian autism families showing that a single-nucleotide polymorphism (SNP) in the MET promoter region — rs1858830 — was associated with autism risk. The functional mechanism is direct and unambiguous: the C allele of rs1858830 disrupts a transcription factor binding site (SP1 family) at the MET promoter, producing a ~2-fold decrease in MET promoter activity. C-allele carriers transcribe substantially less MET protein. The finding was replicated in a 539-family follow-up sample (combined p = 5 × 10−6) and has subsequently been examined in several independent cohorts.

Pillar 2: Postmortem MET Protein Reduction in ASD Cortex

The Campbell et al. 2007 Annals of Neurology paper went directly to the brain. Across postmortem cortical tissue from individuals with ASD and matched controls, MET protein levels were significantly decreased in ASD cortex — specifically in temporal and occipital cortex — accompanied by increased messenger RNA expression for proteins involved in regulating MET signalling activity. This is rare territory in psychiatric neuroscience: a replicated genetic risk variant whose functional consequence (reduced gene transcription) is concordant with a postmortem brain protein finding (reduced protein levels).

Pillar 3: MET, HGF/c-Met and Cortical Glutamatergic Circuit Formation

MET / c-Met is not a generic receptor — it is one of the master regulators of forebrain glutamatergic circuit formation in mammalian cortex. The Eagleson and Levitt group at Children’s Hospital Los Angeles / USC has spent two decades building this story. The 2015 paper (also reported in Developmental Neurobiology) showed that distinct intracellular signalling cascades downstream of c-Met regulate dendritic growth and synaptogenesis, with c-Met conditional knockout in the developing forebrain producing aberrant cortical circuit phenotypes. Mukherjee, Hedrick and others have used neuroimaging to link MET genotype to atypical cortical thickness and functional connectivity in typically developing children and in those at familial risk for autism. The Rudie & Dapretto 2012 Neuron paper linked MET genotype to functional connectivity differences relevant to autism.

Now stop and consider what Dihexa does. Dihexa (PNB-0408) is an angiotensin IV analogue that acts as a positive allosteric modulator of the HGF/c-Met system — the receptor system encoded by the MET gene. The Benoist et al. 2014 JPET paper established that Dihexa’s procognitive and synaptogenic effects are dependent on activation of the HGF/c-Met system: when c-Met signalling is blocked, Dihexa’s effects disappear. The Wright & Harding 2015 review consolidated the broader HGF/c-Met-in-brain story.

The implication is concise: in autism there is converging evidence for reduced MET signalling capacity (genetic, transcriptional, postmortem protein, circuit-imaging). Dihexa is a positive allosteric modulator that augments c-Met signalling. On paper this is the cleanest mechanistic match between Dihexa and any psychiatric condition. Whether augmenting c-Met signalling in an adult brain that developed under reduced MET signalling can meaningfully rescue circuit function, or whether the developmental window that mattered has long since closed, is an empirical question that has never been addressed in a single human trial.

Pillar 4: MET, the Immune System and Air-Pollution Interaction

The story does not stop at genetics. The Heuer 2011 Translational Psychiatry paper linked MET genotype to autism-associated maternal autoantibodies and cytokine expression, embedding the MET story within the broader maternal immune activation (MIA) framework popularised by the Patterson and Choi labs. The Volk 2014 Epidemiology paper reported a gene-environment interaction between MET genotype and air-pollution exposure on autism risk — one of the cleanest replicated G×E findings in autism epidemiology.

This matters because it gives a coherent biological story: an environmental insult acting during fetal cortical development on a genetically vulnerable c-Met pathway. The downstream consequences for cortical wiring, synaptogenesis and excitation-inhibition balance map directly onto the broader autism cortical phenotype seen in the Hedrick 2012 NeuroImage cortical thickness study, the Ecker / Murphy MRI work and the ABIDE Di Martino 2014 Molecular Psychiatry functional-connectivity consortium analysis.

The January 2026 mGluR5 PET Finding: 16-23% Lower Cortical Availability in Autism

The January 2026 brain-wide PET imaging study published in early 2026 (PubMed 41366835) is the biggest neuroimaging news in autism this year. Using the specific binding tracer [18F]FPEB for metabotropic glutamate receptor 5 (mGluR5), researchers reported pervasively lower mGluR5 availability across cortical regions in autistic adults compared to neurotypical controls, with reductions of:

• −23% in the left frontal pole
• −23% in the left cingulate
• −19% in the frontal lobe
• −19% in the temporal lobe
• −19% in the cerebellum
• −18% in the fusiform gyrus
• −16% to −23% overall brain-wide

The Carbonell-Roig & Aviles-Olmos 2026 Journal of Neural Transmission review consolidated the broader mGluR5-in-autism evidence base across genetic, molecular, neuroimaging and therapeutic levels.

This is biologically important because mGluR5 is a central node in cortical excitatory glutamate signalling, is the receptor whose hyperactivation in Fragile X syndrome (FMR1 loss) gives rise to the canonical ‘mGluR theory of Fragile X’ (Bear, Huber, Warren), and is the target of multiple failed autism drug programmes — mavoglurant (Roche), basimglurant (Roche), and the AFQ056 fragile X programme that defined the failure mode for negative allosteric modulators in this space. The Fatemi pilot PET study previously reported elevated mGluR5 binding in postcentral gyrus and cerebellum of male individuals with autism, while the new 2026 brain-wide study reports the opposite directionality across broader cortex — an indication that mGluR5 dysregulation in autism is regional, heterogeneous and not yet fully understood.

The connection to Dihexa is that BDNF/HGF synaptogenic signalling and mGluR5-dependent synaptic plasticity converge on the same long-term depression (LTD) and dendritic spine biology. mGluR5-LTD requires local protein synthesis; BDNF/TrkB signalling drives the local translation machinery; HGF/c-Met signalling regulates dendritic spine density. A peptide that augments c-Met signalling will plausibly act, downstream, on the same plasticity machinery that the January 2026 PET data show to be altered in autism. Whether that intervention restores or further disrupts a system that is already 16-23% off baseline is an empirical question, not a theoretical one.

December 2025 DAYBUE STIX: The Only FDA-Approved Drug for a Core Autism-Spectrum Indication in 2026

On 12 December 2025, the FDA approved DAYBUE STIX (trofinetide for oral solution, powder formulation) from Acadia Pharmaceuticals for the treatment of Rett syndrome in adult and paediatric patients aged 2 years and older. The approval was reported in detail by HCPLive, Neurology Advisor, Acadia’s press release, and Pharmaceutical Technology. The new powder formulation is dye- and preservative-free and was approved on the back of a bioequivalence study to the original oral solution. DAYBUE STIX is available on a limited basis in Q1 2026 with broader US launch in Q2 2026.

The original trofinetide (DAYBUE) approval in March 2023 was based on the Phase 3 LAVENDER trial in girls and women with Rett syndrome and remains the only FDA-approved treatment for Rett syndrome. Acadia licensed the molecule from Neuren Pharmaceuticals (Australia). Trofinetide is a synthetic glypromate analogue — a tri-peptide derivative of IGF-1 (insulin-like growth factor 1) — and is structurally and mechanistically unrelated to Dihexa. The closest mechanistic parallel is that both molecules are small peptide modulators of growth-factor signalling pathways involved in synaptic plasticity, but they act on entirely different receptor systems (IGF-1R / NNZ-2566 for trofinetide; HGF/c-Met for Dihexa).

The relevance to a Dihexa-for-autism discussion is twofold. First, DAYBUE proves that regulators will approve drugs for narrow neurodevelopmental indications when there is solid Phase 3 evidence — the pathway exists. Second, Rett syndrome is a single-gene disorder (MECP2, X-linked, ~1 in 10,000-15,000 girls) which is mechanistically and developmentally distinct from idiopathic autism, even though Rett was historically grouped with the autism spectrum in DSM-IV. The translation from a single-gene-target trial in Rett to the heterogeneous, polygenic, common-variant landscape of idiopathic autism is one of the most demanding translation problems in neuropsychiatry.

The wider Rett pipeline is active. The International Rett Syndrome Foundation pipeline page tracks the ongoing programmes — including Taysha Gene Therapies’ TSHA-102 AAV9-MECP2 gene therapy (REVEAL trial), Neurogene’s NGN-401 MECP2 gene therapy programme, and several MECP2 reactivation approaches. None has any direct relevance to broader autism.

March 2026 Leucovorin: A Cautionary Tale for Autism Drug Development

The March 2026 FDA decision on leucovorin (folinic acid) is the most important policy story of 2026 for autism families, and the most important cautionary tale for anyone considering unproven biological treatments for autism.

The narrative arc is short and clear. In September 2025 the FDA fast-tracked leucovorin for cerebral folate deficiency (CFD), reflecting the small but real body of evidence that some children with autism-spectrum presentations have folate receptor alpha autoantibodies (FRAA) that block folate transport across the blood-brain barrier, and that leucovorin (a folate analogue) can partially restore CNS folate. The 2018 Frye et al. Molecular Psychiatry randomised trial in 48 autistic children with FRAA had reported improvements in verbal communication.

Then on 10 March 2026 the FDA approved leucovorin only for cerebral folate deficiency in patients with a confirmed variant in the FOLR1 gene — an ultra-rare condition affecting fewer than 1,000 individuals globally — and explicitly stated that there is insufficient evidence to support using leucovorin for autism. The decision followed the January 2026 retraction of the Panda et al. European Journal of Pediatrics randomised trial — the largest study supporting leucovorin in autism — after independent reviewers identified data inconsistencies the journal could not reconcile (NPR coverage, January 2026).

The full context was set out by:

• The 2026 New England Journal of Medicine Perspective piece on cerebral folate deficiency, autism, and the role of leucovorin.
• The 2026 PubMed-indexed clinical concerns paper on leucovorin use in ASD.
• The American Academy of Pediatrics FAQ for paediatricians.
• The EBM Focus evidence review.
• The MedShadow Foundation analysis titled “We Promised Parents a Miracle Autism Treatment. Then We Took It Away.”

The lesson for any subsequent autism intervention claim — including from any quarter of the peptide research-chemical industry — is unambiguous. Autism is a complex, heterogeneous, lifelong condition. Parents and autistic adults are entitled to high-quality evidence before they are asked to take or administer a substance. The bar set by leucovorin is illustrative: a single retracted trial, even with biological plausibility and decades of compassionate use, was not enough for an autism label. A peptide research chemical with zero human trials of any size in any neurodevelopmental population has nothing approaching the evidence base required for any responsible recommendation.

Dihexa, the HGF/c-Met Axis & the Directionality Problem in Neurodevelopment

Dihexa (PNB-0408) is an oral, blood-brain-barrier-penetrant angiotensin IV analogue developed in the Wright and Harding labs at Washington State University. Its proposed mechanism — consolidated in the Benoist et al. 2014 JPET paper, the Wright & Harding 2015 review, and the supporting BDNF and mechanism-of-action deep-dives — is positive allosteric modulation of the HGF/c-Met receptor system, with downstream consequences including:

• Increased BDNF expression and TrkB-dependent dendritic spine formation.
• Increased dendritic arborisation and synaptogenesis in hippocampal and cortical neurons.
• Enhanced long-term potentiation (LTP) at glutamatergic synapses.
• Procognitive effects in scopolamine-amnestic rats and other rodent cognitive models.
• Improvements in spatial memory in mouse Alzheimer’s models (Wright & Harding lab data).

The closest clinical parallel is fosgonimeton (ATH-1017), the Athira Pharma small-molecule HGF/c-Met positive modulator that progressed to Phase 3 in mild-to-moderate Alzheimer’s disease. Fosgonimeton failed its pivotal LIFT-AD Phase 3 trial in September 2023 and the ACT-AD readout was subsequently negative; Athira discontinued the SHAPE Parkinson’s disease dementia (PDD) / dementia with Lewy bodies (DLB) programme. Fosgonimeton has never been tested in autism, Rett, Fragile X, or any neurodevelopmental population.

The Directionality Problem in Autism

The recurring theme of this site’s reviews — rigorously worked through in the fibromyalgia, tinnitus, migraine and OCD reviews — is that synaptogenic, plasticity-promoting peptides have a directionality problem in conditions where pathological plasticity is part of the disorder. Autism makes this problem developmentally acute.

Five directionality risks in autism are worth taking seriously:

1. Critical-period plasticity. Cortical wiring is laid down during sensitive periods that close progressively from infancy through adolescence. A synaptogenic peptide given during these windows has no precedent for safety. The MET-pathway biology that links to autism risk operates in development; whether engaging it in an adult brain can rescue, irrelevantly augment, or destabilise circuits laid down years earlier is unknown.
2. Sensory hyper-responsivity. 70-95% of autistic individuals experience clinically significant sensory hyper-responsivity, reflecting abnormal cortical gain in primary sensory cortices. Augmenting plasticity in these already-overgained circuits could plausibly worsen rather than improve the symptom.
3. Restricted and repetitive behaviours (RRBs). RRBs reflect, in part, over-consolidation of stereotyped neural sequences. A plasticity-promoting intervention could consolidate these patterns further.
4. Anxiety amplification. 40-50% of autistic adults have comorbid anxiety disorders. Limbic plasticity that reinforces threat-association learning is a documented amygdala phenomenon. A peptide that augments plasticity in limbic circuits could plausibly worsen anxiety — the same concern we worked through in detail in the Dihexa for Anxiety & Chronic Stress review.
5. Excitation-inhibition (E/I) imbalance. The January 2026 mGluR5 PET data show that the glutamatergic system in autism is already significantly off baseline. Augmenting BDNF / HGF / TrkB signalling has documented effects on E/I balance through parvalbumin interneuron maturation; the direction of effect in an autism brain is unknown.

Set against these directionality risks is the genuine mechanistic alignment described in section 2 above. The intellectual position is therefore neither “Dihexa obviously helps autism” nor “Dihexa is irrelevant to autism” — it is “The MET-pathway alignment is real and uniquely strong, but the directionality is unknown, the developmental safety is unknown, and the responsible response to a real mechanistic hypothesis is a controlled trial, not self-experimentation in a vulnerable population.”

The 2026 UK Pathway: NICE NG142, NG87, CG142 & the National Autism Strategy

UK autism care is anchored by three principal NICE guidelines, the Autism Act 2009 and the Down Syndrome and Autism Act 2022, the National Autism Strategy 2021-2026, and the cross-government Building the Right Support programme.

NICE NG142 (Under-19s Recognition, Referral & Diagnosis)

NICE NG142 (first published September 2011, updated December 2017 and 2021) is the foundational guideline. Key recommendations include:

• GP and primary-care recognition using validated screening tools (M-CHAT-R/F for 16-30 month-olds, SCQ Social Communication Questionnaire and AQ-10 for older children and young people).
• Referral to a multidisciplinary autism diagnostic team within the local pathway.
• Formal diagnostic assessment using ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition; Lord et al.) and ADI-R (Autism Diagnostic Interview-Revised) or equivalent (DISCO, 3Di).
• Assessment to commence within 13 weeks of referral — the standard now widely breached as documented above.
• Coordinated case management, post-diagnostic feedback to the family, and onward referral for comorbidity assessment.

NICE NG87 (Under-19s Management & Support)

NICE NG87 covers the management of autism in under-19s. Pharmacological recommendations are deliberately narrow:

• Risperidone or aripiprazole off-label for severe irritability or self-injurious behaviour where psychological interventions have failed and risk is significant.
• Methylphenidate, atomoxetine or guanfacine for comorbid ADHD (50-70% comorbidity).
• Melatonin (Slenyto, EU-approved paediatric formulation under NICE TA) for autism-related insomnia after sleep hygiene interventions.
• SSRIs (fluoxetine, sertraline) for comorbid anxiety, depression, OCD under specialist supervision.
• Explicit recommendation against routine use of secretin, chelation, hyperbaric oxygen, exclusion diets, or biomedical interventions outside controlled trials.

NICE CG142 (Adults Diagnosis & Management)

NICE CG142 (June 2012, updated 2021) covers adult autism. The pathway mirrors NG142: GP screening (typically AQ-10), referral to an adult autism diagnostic service, diagnostic assessment using ADOS-2 / ADI-R / DISCO. Adult management emphasises reasonable adjustments under the Equality Act 2010, employment support via Access to Work, mental health treatment for comorbid conditions, and signposting to user-led support (NAS, Ambitious about Autism, local autistic-led organisations).

The Drug-Development Graveyard in Autism Core Symptoms

The history of autism core-symptom pharmacology is sobering and explains why NICE is properly cautious. Major Phase 3 failures include:

• Bumetanide (Servier; SIGN1 and SIGN2 Phase 3 trials in children and adolescents) — failed September 2021.
• Balovaptan (Roche; V1A vasopressin receptor antagonist) — failed 2020 in adults.
• Arbaclofen / STX209 (Seaside Therapeutics) — failed.
• Mavoglurant / AFQ056 (Roche; mGluR5 negative allosteric modulator) — failed in Fragile X 2014; broader autism programme not pursued.
• Basimglurant (Roche; mGluR5 NAM) — failed in Fragile X 2014.
• Intranasal oxytocin — Sikich et al. 2021 NEJM negative Phase 2; Quintana & Westlye 2025 meta-analysis equivocal.
• Cannabidiol (CBD) — the Aran 2021 Frontiers open-label work was promising but lacked controlled replication.
• N-acetylcysteine (NAC) — Hardan 2012 Biological Psychiatry positive pilot; replication mixed.
• Sulforaphane — Singh & Talalay 2014 PNAS Phase 2 promising; not yet replicated at scale.
• Faecal microbial transplant (MTT) — Kang 2017 / 2019 Microbiome; not approved for autism.

This is the empirical context in which any peptide intervention has to be judged. Several molecules with stronger mechanistic and human-trial pedigrees than Dihexa have failed at Phase 3.

Autism Genetics, Syndromic Causes & Comorbidities Relevant to Dihexa

Autism is one of the most heritable common neuropsychiatric conditions, with twin-study heritability estimates of approximately 80-90% (Tick, Bolton, Happe 2016 Molecular Psychiatry meta-analysis). The architecture is complex:

• De novo single-nucleotide variants — Iossifov, Sanders et al. 2014 Nature across the SSC (Simons Simplex Collection).
• Copy number variants (CNVs) — including 15q11-13, 16p11.2, 22q11.2, 22q13.3 (Phelan-McDermid).
• Common-variant polygenic risk — Grove, Børglum et al. 2019 Nature Genetics autism GWAS.
• Syndromic autism — Fragile X (FMR1, ~1 in 4,000 males), Rett syndrome (MECP2, ~1 in 10,000-15,000 girls), Angelman (UBE3A 15q11-13), Phelan-McDermid (SHANK3 22q13, ~1 in 8,000-15,000), tuberous sclerosis (TSC1/TSC2, ~50% comorbid autism), CHARGE (CHD7), Smith-Magenis (RAI1), Williams (7q11.23 deletion, ELN), and Down syndrome (16-19% ASD comorbidity).

The SFARI Gene database currently catalogues over 1,000 autism-associated genes graded by evidence strength — with SHANK3, CNTNAP2, NRXN1, NLGN3, NLGN4, SYNGAP1, SCN2A, FOXP1, ADNP, CHD8 and MET amongst the most replicated. SPARK (Simons Powering Autism Research) has built a cohort of over 100,000 autistic individuals and family members for genetic and longitudinal study. MSSNG (Autism Speaks) has sequenced over 10,000 whole genomes.

Comorbidities Relevant to Anyone Considering Dihexa

Autism rarely presents in isolation. The comorbidity landscape directly affects any pharmacological intervention:

• ADHD: 50-70% comorbidity (NICE NG87). See the dedicated Dihexa for ADHD review.
• Anxiety disorders: 40-50% (social anxiety, generalised anxiety, OCD). See the Dihexa for Anxiety & Stress and Dihexa for OCD reviews.
• Depression: 25-40% lifetime prevalence. See the Dihexa for Depression & Mood review.
• Sleep disorders: 50-80% with insomnia, parasomnias or circadian disruption.
• Epilepsy: 20-30%, particularly in those with intellectual disability.
• Intellectual disability: 30-50%.
• Gastrointestinal disorders: IBS, GERD, functional constipation.
• Eating disorders: ARFID (avoidant/restrictive food intake disorder), anorexia nervosa (PEACE pathway 2024 NICE).
• Gender dysphoria: 6-26% in autistic populations (Warrier 2020 Nature Communications).
• hEDS / hypermobility / MCAS: 22% Ehlers-Danlos overlap (Cederlof 2016; Casanova 2020).
• PTSD and complex trauma: elevated rates reflecting both bullying / abuse exposure and difficulties with safety in social contexts.

Anyone considering an intervention should recognise that autism almost always presents with one or more of these comorbidities, that each has its own evidence-based pathway, and that an unproven peptide is not a substitute for diagnosis, monitoring and treatment of the comorbid condition.

The Practical UK Pathway for Suspected Autism in 2026

For anyone in the UK with concerns about autism — in themselves, their child, or a family member — the evidence-based pathway in 2026 is as follows:

For Children & Young People

1. Talk to your GP, health visitor or school SENCO. The GP can complete a basic screening (M-CHAT-R/F for 16-30 month-olds, SCQ for older children) and refer to the local community paediatric / CAMHS autism diagnostic pathway.
2. Multidisciplinary diagnostic assessment. NICE NG142 mandates a multidisciplinary team typically including a paediatrician or child psychiatrist, a speech and language therapist, an occupational therapist and a clinical / educational psychologist. Diagnostic instruments include ADOS-2 and ADI-R (or DISCO / 3Di).
3. Post-diagnostic support. Education Health Care Plans (EHCPs) under the SEND code of practice, school SENCO involvement, IPSEA advice for SEND tribunal where needed. The Down Syndrome and Autism Act 2022 strengthens local authority duties.
4. Comorbidity assessment. ADHD assessment (very high comorbidity rate), CAMHS referral for anxiety / depression / OCD as needed.
5. Pharmacological support if appropriate. Strictly within NICE NG87 framework — for comorbid ADHD, severe irritability, sleep, or specific comorbid mental health conditions.

For Adults

1. GP referral. Complete the AQ-10 (Adult Autism Quotient short form) with your GP; a score of 6+ supports referral.
2. NHS adult autism diagnostic service. The Adult Autism Diagnostic and Consultation Service (AADCS, hosted at London Waiting Room) is the principal NHS-funded London pathway. ICB-level adult autism services exist across England with variable capacity.
3. Right-to-Choose alternative. Under the NHS Constitution, English adults can choose any provider holding an NHS contract. Psychiatry-UK, ProblemShared and Clinical Partners are commonly used; The Retreat Clinics publishes a comparison of current waiting times.
4. Private pathway. Self-funded assessment typically £1,500-£3,500.
5. Post-diagnostic support. NAS post-diagnostic groups, Access to Work for employment support, Equality Act 2010 reasonable adjustments, mental-health support for comorbidities.

UK Charities & Support Organisations

• National Autistic Society (NAS) — the largest UK autism charity; helpline 0808 800 4104.
• Autistica — the UK’s leading autism research charity (Research Autism merged with Autistica in 2025).
• Ambitious about Autism — young-people-focussed support and policy.
• Mencap — learning disability charity with significant autism overlap.
• IPSEA — Independent Provider of Special Education Advice for SEND tribunal support.
• NIHR Be Part of Research — UK clinical-trial portal for autism studies.

BDNF, Synaptic Plasticity & the Broader Growth-Factor Story in Autism

The wider growth-factor / neurotrophin story in autism extends well beyond MET and HGF. The Dihexa & BDNF mechanistic deep-dive covers the broader BDNF biology that converges on the same plasticity machinery the autism phenotype implicates.

Key points relevant to autism:

• The BDNF Val66Met polymorphism (rs6265) — which reduces activity-dependent BDNF secretion — has been examined in autism with the Hashimoto / Sakai 2016 meta-analysis showing modest but inconsistent effects on autism risk.
• Multiple studies (Garcia-Penas, Connolly, Nelson 2003 Pediatrics; Tsai 2008) have reported elevated serum BDNF in autistic children and even in newborns later diagnosed with autism — the opposite directionality from depression or Alzheimer’s. This is the same directionality paradox we discussed in the fibromyalgia review.
• Cerebellar Purkinje cell BDNF expression is altered in postmortem autism cortex (Tsai 2008 and follow-up work).
• BDNF/TrkB signalling drives the local translation machinery that mGluR5-LTD also engages — tying the BDNF and mGluR5 stories together.

The pattern is a recurring caution: where peripheral BDNF is elevated in a condition, a BDNF-upregulating intervention is mechanistically in the wrong direction. Whether central (CNS) BDNF moves in parallel with peripheral BDNF is not always clear, but the directionality question is real.

Ethics, Safeguarding & the Particular Vulnerability of the Autism Community

The autism community has, over decades, been subjected to an unusual volume of unproven, harmful and exploitative biological treatments. Chelation, MMS / chlorine dioxide, hyperbaric oxygen, secretin, exclusion diets, faecal microbial transplant outside trial protocols, stem cell tourism, and a long list of supplement protocols have all been marketed as autism “treatments” with little or no evidence and sometimes serious harm. National Autistic Society, Autistica and other reputable UK autism bodies have published cautions against unproven biological treatments precisely because the population is vulnerable to false hope.

Anyone considering an unapproved peptide should weigh three additional considerations specific to the autism context:

1. Paediatric safeguarding. Administering an unapproved substance to a child can attract attention from social services or the relevant local authority safeguarding team. The Children Act 1989 and Working Together to Safeguard Children statutory guidance treat the administration of unapproved or unproven medical treatments to a child as potentially relevant to safeguarding depending on circumstances and the child’s capacity to consent.
2. Capacity and consent. Autistic adults have, on average, the same capacity for medical decision-making as anyone else, but the Mental Capacity Act 2005 framework matters where co-occurring intellectual disability is present. The Down Syndrome and Autism Act 2022 strengthens the framework around supported decision-making.
3. Cumulative trial harms. Multiple concurrent unproven interventions (peptide stacks, supplement protocols, diets, devices) make it impossible to identify what is helping or harming and concentrate harm and confusion onto the autistic person.

The responsible path for anyone with a serious mechanistic interest in c-Met-pathway pharmacology in autism is engagement with the formal clinical-trial ecosystem: Autistica’s research priorities, the NIHR Be Part of Research portal, the MRC autism research call, and the European Autism Interventions / EU-AIMS framework. A controlled trial in a well-defined autism population, with proper paediatric safeguards if relevant, is what the science and the community require — not self-experimentation.

Bottom Line: Dihexa & Autism in 2026

The MET-pathway alignment between Dihexa’s pharmacology and the molecular biology of autism is the strongest mechanistic case for any psychiatric or neurological condition this site has reviewed. The Campbell rs1858830 promoter C-allele autism association, the postmortem MET protein reduction in ASD cortex, the Eagleson & Levitt cortical-circuit work, the gene-environment interaction with air pollution, and the convergence with the January 2026 mGluR5 PET findings together describe a coherent biological story in which Dihexa’s c-Met-activating pharmacology is, on paper, directionally aligned with one of the better-replicated mechanistic accounts of autism risk.

And it is still entirely unproven.

There are zero human Dihexa trials in any neurodevelopmental population. There is no paediatric safety data of any kind. The closest clinical-stage HGF/c-Met molecule (fosgonimeton) failed its pivotal Alzheimer’s Phase 3. The mGluR5 PET data show a glutamatergic system already 16-23% off baseline. The recent leucovorin story illustrates how easily even a biologically plausible autism intervention can fail to meet regulatory evidence bars. The directionality risks — sensory hyper-responsivity, RRBs, anxiety amplification, E/I imbalance, critical-period plasticity — are real, not theoretical.

For autistic children, adolescents and adults in the UK in 2026, the evidence-based pathway is:

• Diagnostic assessment under NICE NG142 (under-19s) or CG142 (adults).
• Post-diagnostic support under NICE NG87 with pharmacological treatment reserved for comorbid conditions only.
• Reasonable adjustments under the Equality Act 2010 and EHCPs under SEND legislation.
• Comorbidity treatment via the relevant NICE pathways (ADHD NG87, anxiety, depression, OCD CG31, sleep, epilepsy NG217).
• Engagement with the National Autistic Society, Autistica and other UK autism organisations.
• Participation in well-designed clinical trials via the NIHR Be Part of Research portal — including any future c-Met-pathway trial in a properly designed autism cohort.

Dihexa is not part of that pathway in 2026, and on the current evidence base it cannot be recommended for autism, ASD, Asperger’s, Rett syndrome, Fragile X syndrome or any neurodevelopmental disorder. The mechanistic case is real and unusually strong; the clinical case is absent. Those two facts have to be held together.

Selected References & External Sources

1. NICE NG142 (Sep 2017; updated 2021). Autism spectrum disorder in under 19s: recognition, referral and diagnosis. — nice.org.uk/guidance/ng142
2. NICE NG87 (Aug 2013; updated 2021). Autism spectrum disorder in under 19s: support and management. — nice.org.uk/guidance/ng87
3. NICE CG142 (June 2012; updated 2021). Autism spectrum disorder in adults: diagnosis and management. — nice.org.uk/guidance/cg142
4. Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, Elia M, Schneider C, Melmed R, Sacco R, Persico AM, Levitt P (2006). A genetic variant that disrupts MET transcription is associated with autism. PNAS USA. — PubMed 17030808
5. Campbell DB, D’Oronzio R, Garbett K, Ebert PJ, Mirnics K, Levitt P, Persico AM (2007). Disruption of cerebral cortex MET signaling in autism spectrum disorder. Annals of Neurology. — PubMed 17696172
6. Heuer L et al. (2011). Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression. Translational Psychiatry. — Nature
7. Eagleson KL, Lane CJ, McFadyen-Ketchum L, Solak S, Wu HH, Levitt P (2015). The autism-associated MET receptor tyrosine kinase engages early neuronal growth mechanism and controls glutamatergic circuits development in the forebrain. Molecular Psychiatry. — Nature MP
8. Hedrick A et al. (2012). Autism risk gene MET variation and cortical thickness in typically developing children and adolescents. NeuroImage. — PubMed 23097380
9. Volk HE et al. (2014). Autism spectrum disorder: interaction of air pollution with the MET receptor tyrosine kinase gene. Epidemiology. — PubMed 24240654
10. Russell G et al. / Brett D et al. (2023). Autism in England: assessing underdiagnosis in a population-based cohort study of prospectively collected primary care data. BJGP. — PMC10114511
11. NHS England Digital. Autism Statistics, April 2025 to March 2026. — digital.nhs.uk autism statistics
12. NHS England (March 2026). ADHD and Autism Payment Guidance 2026-27. — england.nhs.uk PDF
13. National Autistic Society (November 2025). Autism assessment waiting times November 2025. — autism.org.uk
14. Nuffield Trust. The rapidly growing waiting lists for autism and ADHD assessments. — nuffieldtrust.org.uk
15. NHS England Long Read. National framework to deliver improved outcomes in all-age autism assessment pathways. — england.nhs.uk
16. The Retreat Clinics (2026). ADHD & Autism Waiting Times UK 2026 (NHS, RTC & Private). — theretreatclinics.org.uk
17. Mecholy / Murphy et al. (2026). Imaging Metabotropic Glutamate Receptor 5 and Excitatory Neural Activity in Autism. — PubMed 41366835
18. Carbonell-Roig J, Aviles-Olmos I (2026). Unraveling mGluR5 dysfunction in autism spectrum disorder: a multi-level analysis of genetic, molecular, and neurobiological mechanisms. Journal of Neural Transmission. — Springer
19. Mecca AP et al. (2022 / 2024 KOL update). From bench to bedside: the mGluR5 system in people with and without Autism Spectrum Disorder. Translational Psychiatry. — Nature TP
20. Acadia Pharmaceuticals (12 December 2025). DAYBUE STIX (trofinetide) for oral solution — new powder formulation FDA approved for Rett syndrome. — Acadia press release · Pharmaceutical Technology · HCPLive · Neurology Advisor
21. International Rett Syndrome Foundation. Rett Research & Clinical Pipeline. — rettsyndrome.org
22. FDA (10 March 2026). Leucovorin approval for cerebral folate deficiency (FOLR1). — AJMC
23. NPR (22 January 2026). Can the prescription drug leucovorin treat autism? History says, probably not. — NPR
24. MedShadow Foundation. We Promised Parents a Miracle Autism Treatment. Then We Took It Away. — medshadow.org
25. NEJM Perspective (2026). Cerebral Folate Deficiency, Autism, and the Role of Leucovorin. — nejm.org
26. EBM Focus. Leucovorin — A Trending Autism Treatment in Search of Supporting Evidence. — ebsco.com
27. American Academy of Pediatrics (2026). Leucovorin Use in Autistic Pediatric Patients — FAQs. — aap.org
28. Clinical concerns and considerations for leucovorin use in autism spectrum disorder (2026). — PubMed 41670435
29. Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Wright JW, Harding JW (2014). The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. — PubMed 24403718
30. Wright JW, Harding JW (2015). The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. — PubMed 25711386
31. Tick B, Bolton P, Happé F, Rutter M, Rijsdijk F (2016). Heritability of autism spectrum disorders: a meta-analysis of twin studies. Molecular Psychiatry.
32. Grove J et al. (2019). Identification of common genetic risk variants for autism spectrum disorder. Nature Genetics.
33. Iossifov I, Ronemus M, Levy D et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. Nature.
34. Lai MC, Lombardo MV, Auyeung B, Chakrabarti B, Baron-Cohen S (2015). Sex/gender differences and autism: setting the scene for future research. Molecular Autism.
35. National Autistic Society UK. — autism.org.uk · helpline 0808 800 4104
36. Autistica UK research charity. — autistica.org.uk
37. Ambitious about Autism. — ambitiousaboutautism.org.uk
38. SFARI Gene autism database, Simons Foundation. — sfari.org
39. SPARK for Autism research cohort, Simons Foundation. — sparkforautism.org
40. NIHR Be Part of Research portal — UK autism trials. — bepartofresearch.nihr.ac.uk
41. Priory Group. Autism Statistics UK 2026. — priorygroup.com
42. UK Autism Act 2009 · Down Syndrome and Autism Act 2022 · National Autism Strategy 2021-2026 (HM Government).